FDA calendar · March 2023 · built from SEC filings

PDUFA dates March 2023: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in March 2023. The FDA calendar also recorded 32 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in March 2023

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

March 2023: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Mar 2023Month disclosedDAYBUE (trofinetide)ACADFDA approvalRett syndromeApprovedSEC Form 10-Q
Mar 2023Month disclosedLUMYKRAS™ (sotorasib)AMGNComplete Response Letter—CRL issuedSEC Form 10-Q
March 1, 2023Arnuity Ellipta (fluticasone furoate)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
Mar 2023Month disclosedJAKAFI (ruxolitinib)INCYComplete Response Letter—CRL issuedSEC Form 10-Q
Mar 2023Month disclosedZYNYZ (retifanlimab)INCYFDA approvalwith metastatic or recurrent locally advanced Merkel cell carcinomaApprovedSEC Form 10-Q
Mar 2023Month disclosedJoenja® (leniolisib)PHARLabel expansion—ApprovedSEC Form 8-K
March 3, 2023Udenyca (pegfilgrastim-cbqv)CHRSLabel expansion—ApprovedopenFDA Drugs@FDA
March 3, 2023VERZENIO (abemaciclib)LLYLabel expansion—ApprovedopenFDA Drugs@FDA
March 3, 2023Revatio® (sildenafil)VTRSLabel expansion—ApprovedopenFDA Drugs@FDA
March 6, 2023APONVIE® (aprepitant)HRTXFDA approval—ApprovedSEC 8-K Exhibit 99.1
March 9, 2023Zavzpret ® (zavegepant)PFEFDA approvalTo treat migraineDrug Trails SnapshotApprovedSEC Form 10-K
March 13, 2023LIVMARLI® (maralixibat)MIRMLabel expansion—ApprovedopenFDA Drugs@FDA
March 15, 2023Gozellix (gallium ga-68 gozetotide)TLXLabel expansion—ApprovedopenFDA Drugs@FDA
March 16, 2023Tafinlar (dabrafenib mesylate)NVSFDA approval—ApprovedopenFDA Drugs@FDA
March 16, 2023Tafinlar (dabrafenib mesylate)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
March 16, 2023Mekinist (trametinib dimethyl sulfoxide)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
March 16, 2023Mekinist (trametinib; trametinib dimethyl sulfoxide)NVSFDA approval—ApprovedopenFDA Drugs@FDA
March 17, 2023Vyalev (foscarbidopa; foslevodopa)ABBVComplete Response Letter—CRL issuedFDA Complete Response Letters
March 21, 2023Evkeeza (evinacumab-dgnb)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
March 22, 2023Amjevita (adalimumab-atto)AMGNLabel expansion—ApprovedopenFDA Drugs@FDA
March 22, 2023Zynyz (retifanlimab-dlwr)INCYFDA approvalTo treat metastatic or recurrent locally advanced Merkel cell carcinomaApprovedFDA Novel Drug Approvals
March 24, 2023Fetzima (levomilnacipran hydrochloride)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
March 24, 2023Joenja® (leniolisib)PHARFDA approvalTo treat activated phosphoinositide 3-kinase delta syndromeApprovedSEC Form 8-K
March 28, 2023Vuity (pilocarpine hydrochloride)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
March 28, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
March 30, 2023Omvoh (mirikizumab-mrkz)LLYComplete Response Letter—CRL issuedFDA Complete Response Letters

March 2023: dated readouts

DateDrugCompanyEventIndicationStatusSource
Mar 2023Month disclosedlatozinemab (AL001)ALZNTopline readout—Positivesec_424b
Mar 2023Month disclosedVancomycin Hydrochloride (vancomycin)ARMPTopline readout—PositiveSEC 8-K Exhibit 99.1
Mar 2023Month disclosed—PTGXTopline readout—PositiveSEC Form 10-K
Mar 2023Month disclosed—TARSTopline readoutrosaceaPositiveSEC Form 10-K

March 2023: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Mar 2023Month disclosedPRF-110PRFXTrial start—CompletedSEC 8-K Exhibit 99.1
Mar 2023Month disclosedPRX-115PLXTrial start—CompletedSEC Form 10-K

Questions

What PDUFA dates are in March 2023?

0 PDUFA dates fell in March 2023. The FDA calendar also recorded 32 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.